Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Working Capital Changes: 2019-2024

Historic Other Working Capital Changes for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $10.2 million.

  • Keros Therapeutics' Other Working Capital Changes rose 68.99% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 69.11%. This contributed to the annual value of $10.2 million for FY2024, which is 10.05% up from last year.
  • As of FY2024, Keros Therapeutics' Other Working Capital Changes stood at $10.2 million, which was up 10.05% from $9.3 million recorded in FY2023.
  • Over the past 5 years, Keros Therapeutics' Other Working Capital Changes peaked at $10.2 million during FY2024, and registered a low of $1.5 million during FY2020.
  • Over the past 3 years, Keros Therapeutics' median Other Working Capital Changes value was $9.3 million (recorded in 2023), while the average stood at $7.6 million.
  • Data for Keros Therapeutics' Other Working Capital Changes shows a peak YoY skyrocketed of 179.55% (in 2023) over the last 5 years.
  • Over the past 5 years, Keros Therapeutics' Other Working Capital Changes (Yearly) stood at $1.5 million in 2020, then grew by 5.38% to $1.5 million in 2021, then skyrocketed by 114.53% to $3.3 million in 2022, then skyrocketed by 179.55% to $9.3 million in 2023, then increased by 10.05% to $10.2 million in 2024.